Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Israeli biotech NeoTX lands $45M series C for combo I-O cancer trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Active Biotech","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Receive Milestone Payment From Neotx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Clears NeoTX\u2019s IND Application for Phase 2 Trial of Naptumomab Estafenatox to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Active Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Provides Status Update of its Clinical Naptumomab Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Active Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data on Naptumomab Estafenatox Enhancing CAR-T Cells Potency Presented by Active Biotech\u2019s Partner NeoTX at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Translational Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neotx Announces Successful First Stage Completion of Its Phase 2a Clinical Trial of Naptumomab Estafenatox (Nap), in Combination With Docetaxel in Advanced Non-small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by NeoTX Therapeutics

    Menu

    NeoTX Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              NeoTX Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neotx Announces Successful First Stage Completion of Its Phase 2a Clinical Trial of Naptumomab Estafenatox (Nap), in Combination With Docetaxel in Advanced Non-small Cell L...

              Details:

              Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4.

              Lead Product(s): Naptumomab Estafenatox,Docetaxel,Obinutuzumab

              Therapeutic Area: Oncology Product Name: ABR-217620

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Translational Drug Development

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NeoTX Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Data on Naptumomab Estafenatox Enhancing CAR-T Cells Potency Presented by Active Biotech’s Partner NeoTX at SITC 2021

              Details:

              Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.

              Lead Product(s): Naptumomab Estafenatox,Durvalumab

              Therapeutic Area: Oncology Product Name: ABR-217620

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Active Biotech

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NeoTX Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Active Biotech Provides Status Update of its Clinical Naptumomab Project

              Details:

              The study was amended to also include assessment of pre-treatment with obinutuzumab to assess its effect on anti-drug antibodies (ADAs) to naptumomab.

              Lead Product(s): Naptumomab Estafenatox,Durvalumab

              Therapeutic Area: Oncology Product Name: NAP

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Recipient: Active Biotech

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NeoTX Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              US FDA Clears NeoTX’s IND Application for Phase 2 Trial of Naptumomab Estafenatox to Treat Solid Tumors

              Details:

              Naptumomab Estafenatox, the company’s lead TTS molecule, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells.

              Lead Product(s): Naptumomab estafenatox,Durvalumab

              Therapeutic Area: Oncology Product Name: NAP

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NeoTX Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Active Biotech Receive Milestone Payment From Neotx

              Details:

              In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications.

              Lead Product(s): Naptumomab estafenatox,Durvalumab

              Therapeutic Area: Oncology Product Name: ABR-217620

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Active Biotech

              Deal Size: $71.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NeoTX Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Israeli biotech NeoTX lands $45M series C for combo I-O cancer trials

              Details:

              The company plans to complete the dose escalation phase of the Phase 1b trial of naptumomab estafenatox in combination with durvalumab and continue to develop our patented STR platform.

              Lead Product(s): Naptumomab estafenatox,Durvalumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $45.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing February 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY